Healthcare
No matter how we manage our health, efficacy, risks and costing are top concernsNew reviews of prescription and otc diet drugs or pills of Orlistat for side effect of accute kidney injury
The urgency of removal prescription and over-the-counter (otc) diet drugs or pills of Orlistat (Xenical/Alli, Roche) from the market seem close to the real, because regardless several cases of liver toxicity filed both in medical archives and FDA files, recent reviews report giving more weight petition to kicks this diet drug out of the market.
Despite the FDA has issued precaution use of prescription drug Orlistat in 2010 for severe liver injury based on at least 10 reports that sending 2 patients died caused liver failure and 3 patients hospitalized for liver transplants, and the adverse events report increased afterward for additional acute pancreatitis (47 cases) and kidney stones (73 cases) archived in FDA files, a new report giving more weight risk of side effects for acute kidney injury and acute dialysis.
Based on current review of Orlistat use in Ontario, Canada, since January 2002 and March 2008, 953 patients has taking Orlistats and several adverse events related to acute dialysis or hospital diagnosis of acute kidney injury been reported;
- 5 patients in the 12 months prior to starting on the diet drug, and
- 18 patients within 12 months after filling their prescription.
Reported in the Archives of Internal Medicine on April 12, 2011, the study authors, Dr. Matthew Weir from the University of Western Ontario, London, and colleagues conclude, “In the appropriate setting, physicians should consider orlistat as potential cause of acute kidney injury,” although the study authors in this review can not describe for causality mechanism.
Related Posts:
Subscribe for latest health news via email
